NCT07347210
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07347210
Title Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma (MATVAC-1)
Acronym MATVAC-1
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Centre Hospitalier Universitaire de Besancon
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA

Facility Status City State Zip Country Details
CHU de Besançon Besançon France Details
Centre Georges François Leclerc Dijon France Details
CHU La Timone Marseille France Details
Hôpital Saint-Louis - APHP Paris France Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field